164 related articles for article (PubMed ID: 29223991)
1. A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.
Lyman GH; Poniewierski MS
J Natl Compr Canc Netw; 2017 Dec; 15(12):1543-1550. PubMed ID: 29223991
[TBL] [Abstract][Full Text] [Related]
2. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Link H; Nietsch J; Kerkmann M; Ortner P;
Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
[TBL] [Abstract][Full Text] [Related]
3. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
4. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
6. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
7. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
8. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
9. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
10. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J
BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Choi MR; Solid CA; Chia VM; Blaes AH; Page JH; Barron R; Arneson TJ
Support Care Cancer; 2014 Jun; 22(6):1619-28. PubMed ID: 24492928
[TBL] [Abstract][Full Text] [Related]
12. Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view.
Gascón P; Awada A; Karihtala P; Lorenzen S; Minichsdorfer C
Wien Klin Wochenschr; 2024 Jun; 136(11-12):362-368. PubMed ID: 38010512
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of febrile neutropenia in adults receiving chemotherapy needs to be adapted to the risk.
Georgala A; Klastersky JA
Expert Rev Hematol; 2015 Feb; 8(1):115-21. PubMed ID: 25431921
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.
Lalami Y; Klastersky J
Crit Rev Oncol Hematol; 2017 Dec; 120():163-179. PubMed ID: 29198330
[TBL] [Abstract][Full Text] [Related]
16. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.
Lyman GH; Yau L; Nakov R; Krendyukov A
Ann Oncol; 2018 Sep; 29(9):1903-1910. PubMed ID: 30099478
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
18. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Boccia R; Glaspy J; Crawford J; Aapro M
Oncologist; 2022 Aug; 27(8):625-636. PubMed ID: 35552754
[TBL] [Abstract][Full Text] [Related]
20. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]